NeoGenomics has introduced the Universal Fusion/Expression Profile, one of the first clinically validated next-generation sequencing-based profiles capable of detecting fusion transcripts and analyzing gene expression in 1,385 genes with implications in solid tumors, soft-tissue cancers, and hematologic diseases. The test covers chromosomal translocations that are not currently covered by fluorescence in situ hybridization (FISH) or for cases in which a specific molecular translocation test is not available. This test can address translocations that lead to deregulation of expression when compared to the expression of a proper normal control. The Universal Fusion/Expression Profile sequences all exon regions of the 1385 cancer genes included as part of this profile and has been validated on bone marrow, peripheral blood, FFPE, and fresh tissue.